Related by context. All words. (Click for frequent words.) 72 TAXUS IV 67 TAXUS VI 67 multicenter randomized controlled 67 prospective multicenter 66 randomized Phase III 65 TAXUS ATLAS 65 EVEREST II 65 prospectively defined 65 placebo controlled Phase III 64 multicentre randomized 64 RE LY ® 64 randomized controlled multicenter 64 placebo controlled clinical 64 SPIRIT FIRST 64 phase IIa clinical 64 prospective multicenter randomized 64 phase IIb clinical 64 randomized multicenter 63 paclitaxel eluting stent 63 SPIRIT IV 63 TAXUS Liberte Stent 63 CARE HF 63 TAXUS Express Stent 63 multicenter prospective 63 nonrandomized 63 Val HeFT 63 RE LY 63 pharmacokinetics PK 63 Stenting Trial CREST 63 XIENCE V PROMUS Stent 63 PARTNER Trial 63 multicenter randomized placebo controlled 63 PERSEUS 63 Carotid Revascularization Endarterectomy vs. 63 double blinded randomized 63 multicenter phase 63 ENDEAVOR II 63 prospective randomized multicenter 63 ExTRACT TIMI 63 sirolimus eluting stent 63 p# biomarker 63 HORIZONS AMI trial 62 TAXUS Liberté stent 62 TAXUS Element Stent 62 randomized controlled Phase 62 CYPHER ® Stent 62 Stent Restenosis 62 EchoCRT 62 XIENCE V Everolimus Eluting 62 recurrent GBM 62 PRECiSE 62 everolimus eluting stents 62 CALGB 62 landmark ATHENA 62 ABSORB trial 62 PreCISe 62 LUX Lung 62 randomized multicenter trial 62 angiographic outcomes 62 TRITON TIMI 62 viral kinetic 61 relapsed MM 61 carotid artery stenting CAS 61 MEND CABG 61 active comparator 61 everolimus eluting stent 61 multicentre randomized double 61 TG MV 61 multicenter placebo controlled 61 Vascugel ® 61 prospective randomized controlled 61 multicenter clinical 61 randomized blinded 61 NEVO RES 61 ENDEAVOR clinical 61 pharmacokinetic PK 61 TMC# C# 61 noninferiority 61 ENDEAVOR IV clinical 61 recurrent malignant glioma 61 ToGA 61 STRIDE PD 61 ENDEAVOR III 61 Prostate AdenoCarcinoma Treatment 61 Phase Ib clinical 61 prospective randomized placebo 61 confirmatory clinical 61 XL# SAR# 61 dose escalation Phase 61 PRIMO CABG 61 subanalysis 61 sirolimus eluting 61 AVADO 61 multicenter randomized 61 TAXUS stent 61 EURIDIS 61 BRIM2 60 double blinded placebo 60 PFO migraine 60 sirolimus eluting stents 60 Randomized Evaluation 60 randomized multicentre 60 label multicenter 60 ancrod 60 multicenter Phase III 60 Multicenter 60 Myocardial Infarction Study 60 RESOLUTE 60 zotarolimus 60 Multicenter Automatic Defibrillator Implantation 60 carotid endarterectomy CEA 60 multicenter randomized clinical 60 HCV RESPOND 2 60 crizotinib PF # 60 phase IIIb 60 Phase Ib II 60 ADVANCE PD 60 randomized Phase IIb 60 ENDEAVOR IV 60 Endeavor drug eluting 60 trastuzumab emtansine T DM1 60 BR.# 60 multicenter Phase II 60 EDEMA3 60 CYPHER Stent 60 Taxus Stent 60 lorcaserin Phase 60 acute coronary syndromes ACS 60 ongoing Phase 1b 60 CYPHER R Stent 60 CYPHER R Sirolimus eluting 60 CALGB # [002] 60 fosbretabulin 60 TAXUS Liberte 60 diameter stenosis 60 RECORD1 60 analgesic efficacy 60 neoadjuvant 60 NEVO 60 GAMMAGARD 60 GORE TAG Device 59 TAXUS Liberte Long 59 placebo controlled Phase 59 TAXUS Express 59 mm Stent 59 MIVI III 59 controlled multicenter 59 multicenter randomized double 59 tolerability pharmacokinetics 59 VESTASYNC 59 SPIRIT III 59 PreCISe study 59 subcutaneous PRO 59 prospective nonrandomized 59 PRIMO CABG2 59 paclitaxel eluting stents 59 Phase III VISTA 59 zotarolimus eluting stent 59 NO# [002] 59 Phase IIIb 59 BRIM3 59 Phase III randomized 59 Edge STudy 59 observational cohort study 59 ABCSG 59 TAXUS TM 59 Phase IIIb clinical 59 KRAS mutations occur 59 XIENCE V demonstrated 59 PCI ExTRACT TIMI 59 registrational Phase 59 label multicenter randomized 59 multicentre 59 EXPLORE Xa 59 placebo controlled randomized 59 ASTEROID 59 Kaplan Meier analysis 59 ROCKET AF 59 TAXUS Stent 59 mg/m2 cohort 59 PROMUS Element Stent 59 Phase III placebo controlled 59 multicenter multinational 59 placebo controlled multicenter 59 davunetide intranasal AL 59 IMPACT DCM 59 CLL8 59 VADT 59 Augment Injectable 59 NSABP B 59 evaluable subjects 59 CUSTOM III 59 CHAMPION PCI 59 primary patency 59 dose escalation clinical 59 disease progression TTP 59 rALLy clinical trial 58 PROTECT II 58 binary restenosis 58 MADIT II 58 assessing T DM1 58 prospective randomized 58 coronary drug eluting 58 CR nPR 58 DAPT 58 metastatic HRPC 58 afatinib 58 multicenter 58 Kahalalide F 58 OLYMPIA registry 58 ENESTnd 58 PROSTVAC TM 58 Phase III randomized controlled 58 preclinical efficacy 58 stage IIIb IV 58 APEX PD 58 RE LY trial 58 MIST II 58 MERLIN TIMI 58 PROSTVAC ® 58 drug eluting stent DES 58 biliary tract cancer 58 Long Lesion 58 randomized multicenter Phase III 58 randomized blinded placebo 58 efficacy evaluable 58 CIMZIA TM certolizumab pegol 58 AVOREN 58 label dose escalation 58 XIENCE V stent 58 genotypic resistance 58 NEVO ™ 58 MEND CABG II 58 sunitinib malate 58 CLARITY study 58 Cypher Stent 58 AIR2 Trial 58 liver transplant recipients 58 Angiographic 58 liposomal formulation 58 NCCTG 58 IFN α 58 Phase IIb III 58 Thrombolysis 58 Acute Decompensated Heart Failure 58 IMPACT IMmunotherapy 58 plus prednisone 58 ABSORB clinical 58 DASISION 58 Subgroup analysis 58 Randomised 58 TAXUS Express2 58 dosing cohorts 58 definite stent thrombosis 58 CLORETAZINE TM VNP#M 58 MADIT CRT trial 58 randomized Phase 2b 58 axitinib 58 CLARITY TIMI 58 Phase III psoriasis 58 prospective multicenter study 58 NCIC CTG 58 Sirolimus eluting Coronary Stent 58 label dose titration 57 Phase Ib study 57 treatment naive genotype 57 phase IIb study 57 carotid artery stenting 57 phase III ACCLAIM 57 noninferior 57 mITT population 57 secondary efficacy endpoint 57 ONTARGET 57 multicenter study 57 nab paclitaxel 57 SYNERGY Stent 57 nondiabetic patients 57 TAXUS 57 STEALTH C 57 pain palliation 57 Phase 2a clinical 57 Prospective Randomized 57 Ophena TM 57 BARI 2D 57 pharmacodynamics PD 57 prospective observational 57 pharmacodynamic PD 57 Phase 1a clinical 57 REVIVE Diabetes 57 virologic response 57 Phase #/#a 57 PERSEUS clinical program 57 Clinical Antipsychotic Trials 57 oblimersen 57 Alocrest 57 desvenlafaxine succinate 57 VELCADE melphalan 57 GOUT 57 paclitaxel stent 57 phase III SIMPADICO 57 low dose cytarabine 57 MGd 57 Aplidin 57 riociguat 57 relapsed refractory multiple myeloma 57 phase IIb trial 57 CIMZIA ™ 57 Phase 1b clinical trials 57 Randomized controlled 57 ACUITY trial 57 randomized controlled clinical 57 postintervention 57 BCIRG 57 multicenter Phase 57 Sorafenib HCC Assessment 57 sirolimus stent 57 trastuzumab DM1 T DM1 57 controlled multicenter Phase 57 paclitaxel eluting 57 concurrent chemoradiation 57 randomized clinical 57 Patency 57 TAXUS ® 57 CCX# B 57 cariprazine 57 PROMUS ® 57 azilsartan medoxomil 57 somatostatin analog 57 SWOG 57 SORT OUT III 57 morphometric vertebral fractures 57 NEUVENGE 57 SYNTAX 57 cisplatin vinorelbine 57 RIO Lipids 57 AVERROES 57 ACTEMRA TM 57 dose cohort 57 oral rivaroxaban 57 CONQUER OB 57 Meta analyzes 57 Zilver PTX stent 57 fidaxomicin Phase 3 57 HBeAg negative patients 57 substudy 57 Edwards SAPIEN valve 57 doxorubicin docetaxel 57 satraplatin Phase 57 prospectively randomized 57 RTOG 57 Azedra 57 drug eluting coronary stent 57 multicentre prospective 57 mRCC 57 PROTECT AF 57 ORMD 56 RAVEL 56 alvespimycin 56 Phase 1b clinical 56 ZYBRESTAT fosbretabulin 56 TMC# r 56 CIMZIA TM 56 Scandinavian Cardiac Outcomes 56 TM Everolimus Eluting 56 phase IIa 56 Prospective Randomized Trial 56 Phase 2b kidney transplant 56 FOLFOX4 56 ACCORD Lipid 56 placebo controlled dose escalation 56 Phase III confirmatory 56 tanespimycin 56 carotid stenting 56 evaluating tivozanib 56 rapid virologic response 56 CALERIE 56 elacytarabine 56 ECASS 56 V Everolimus Eluting Coronary 56 retrospective cohort 56 GEM OS1 56 phase Ib clinical 56 stent restenosis 56 BOLDER II 56 stent DES 56 DES implantation 56 #mg QD [002] 56 pivotal bioequivalence 56 masked placebo controlled 56 MIVI TRUST 56 NATRECOR R 56 metaglidasen 56 MAGE A3 ASCI 56 GORE VIABAHN Endoprosthesis 56 pharmacodynamic profiles 56 TPV r 56 Dr. Kandzari 56 retrospective observational study 56 Sirolimus eluting 56 MADIT CRT 56 secondary efficacy endpoints 56 PEG IFN 56 ARCOXIA 56 efficacy endpoint 56 PLCO 56 Acute Myocardial Infarction 56 AIR CF2 56 Phase 2b clinical 56 unfractionated heparin UFH 56 galiximab 56 NSABP 56 Complications Trial 56 ACTIVE W 56 ACRIN 56 Xanafide 56 pharmacodynamic profile 56 OvaRex MAb 56 GRAVITAS trial 56 mCRPC 56 pharmacokinetic PK study 56 cytoreductive nephrectomy 56 PROactive study 56 neratinib 56 APPRAISE 56 teriflunomide 56 Histologic 56 radiation dosimetry 56 angiographically 56 Phase 2a trial 56 REALITY Trial 56 plus dexamethasone 56 achieved CCyR 56 HCV SPRINT 56 mCRC patients 56 trials RCTs 56 adenoma recurrence 56 Primary endpoints 56 Randomized Phase 56 TEMSO 56 SYNTAX trial 56 huN# DM1 56 Phase 2b monotherapy 56 Sibutramine Cardiovascular Outcomes 56 Echocardiographic 56 Infarct 56 metastatic CRC 56 APTIMA HPV 56 Amrubicin 56 underwent resection 56 Stent System 56 clevidipine 56 Events MACE 56 brivaracetam 56 Prostate Lung Colorectal 56 ADAGIO study 56 NSTE ACS 56 MarginProbe 56 melphalan prednisone 56 Atherosclerosis MESA 56 gemcitabine carboplatin 56 irbesartan 56 Phase III ADT 56 SIMPADICO 56 dosage regimens 56 IN.PACT 56 MitraClip device 56 Phase 2b randomized 56 thorough QT 56 fluvastatin 56 HGS ETR2 56 pCR 56 cediranib 56 elotuzumab 56 NCCTG N# 56 olmesartan 56 ADMIRE HF 56 PROMUS R 56 Phase Ib IIa 56 antiretroviral naïve 56 LEXIVA r 56 EORTC 56 recurrent NSCLC 56 MYDICAR ® 56 pharmacokinetic pharmacodynamic 56 comparing XIENCE V 56 SABCS 56 ischemic cardiomyopathy 55 Phase IIB 55 RG# ITMN 55 blind randomized controlled 55 NEVO TM 55 evaluating REVLIMID 55 preintervention 55 CANCIDAS 55 Randomized Clinical Trial 55 Vascugel 55 multicentre randomized controlled 55 EGFR HER2 55 dosing cohort 55 eluting stent 55 PSMA ADC 55 paricalcitol 55 multicenter clinical trials 55 BRAF inhibitor 55 EINSTEIN DVT 55 de novo coronary 55 oncologic outcomes 55 colorectal adenoma 55 Folfox 55 gefitinib Iressa 55 RAPAFLO R 55 blind randomized placebo 55 PICSO ® 55 Endarterectomy 55 RRMS patients 55 rt PA 55 Gynecologic Oncology Group 55 phase IIb 55 novel VDA molecule 55 Vascular Wrap 55 locoregional disease 55 ZOLINZA 55 Acute Ischemic Stroke 55 postmenopausal osteoporotic women 55 prospective multicentre 55 fallopian tube cancers 55 DCCT 55 blind multicenter 55 Pivotal Trial 55 ENGAGE AF TIMI 55 undetectable HBV DNA 55 Tarceva TM 55 CBLC# 55 ACCEDE 55 blinded randomized placebo controlled 55 ZYBRESTAT TM 55 REMINYL ® 55 maximally tolerated dose 55 placebo controlled 55 comparator arm 55 SCD HeFT 55 echocardiographic parameters 55 HDL Selective Delipidation 55 adjuvant tamoxifen 55 XmAb# 55 Operative mortality 55 multicenter randomized Phase 55 dose escalation trial 55 Phase IIb clinical 55 reintervention 55 CUSTOM II 55 microbiologically evaluable 55 Phase #b/#a clinical 55 renal artery stenting 55 TAXUS Liberté 55 Vidaza ® 55 Pharmacokinetic 55 Phase III ThermoDox 55 treatment naïve genotype 55 Hemodynamic 55 dipyridamole plus 55 GetGoal Phase III 55 ERSPC 55 prognostic variables 55 solithromycin 55 restenotic lesions 55 sipuleucel T 55 Tyrima 55 composite endpoint 55 biochemical recurrence 55 decitabine 55 transfemoral 55 vidofludimus 55 ZACTIMA 55 Ceplene/IL-2 55 CCX# 55 CYPHER ® Sirolimus eluting 55 randomized #:#:# 55 pharmacokinetic parameters 55 Ophena 55 CATIE AD 55 Doxil ® 55 Pivotal Phase III 55 HeFT 55 Intervention Effectiveness 55 GENASIS trial 55 Cloretazine 55 EOquin TM 55 phase Ib 55 ARDIS 55 VITAL Trial 55 CAMMS# 55 IFN alfa 55 TRA 2P 55 imetelstat 55 CURE AF 55 BrachySil TM 55 blind randomized multicenter 55 TAXUS R 55 XIENCE TM 55 Afatinib 55 symptomatic VTE 55 CYPHER R stent 55 recurrent glioblastoma multiforme 55 Hazard Ratio 55 photocoagulation 55 MVax R 55 fully bioabsorbable 55 prospectively stratified 55 EMPHASIS HF trial 55 Cloretazine ® 55 prostate carcinoma 55 oral ridaforolimus 55 myoblast 55 VerifyNow P#Y# 55 pharmacodynamics 55 Secondary efficacy endpoints 55 prespecified 55 Left Ventricular Dysfunction 55 pharmacodynamic markers 55 ONCONASE R 55 darunavir ritonavir 55 SYMMETRY trial 55 RE SURGE 55 ipsilateral stroke 55 LCP AtorFen 55 mg BID dose 55 number NCT# ClinicalTrials.gov 55 CRLX# 55 dose dose escalation 55 Intravail R 55 CryoMaze 55 coronary stenting 55 cardiac perfusion 55 pretransplant 55 Phase IIa trial 55 ISAR TEST 55 AKT inhibitor 55 tipranavir r 55 free survival PFS 55 MYTHOS trial 55 fidaxomicin Phase 55 non valvular atrial 55 standard chemotherapy regimen 55 prospective observational cohort 55 cathepsin K inhibitor 55 HER2 expression 55 Epanova 55 segment binary restenosis 55 blind placebo 55 EDEMA3 trial 55 EVIZON 54 Initiated Phase 54 clinically localized prostate 54 intravenous dosing 54 Annexin V 54 kidney allograft 54 SUPERA stent 54 Teriflunomide 54 initiated Phase Ib 54 Randomized Study 54 Myocardial Infarction 54 dose atorvastatin 54 epoetin alpha 54 bi ventricular pacing 54 STOP AF 54 Osteoporotic Fractures 54 Trial ASCOT 54 median PFS 54 label multicenter Phase 54 prucalopride 54 icatibant 54 NCT# ClinicalTrials.gov 54 oral FTY# 54 retinal vein occlusion induced 54 PSADT 54 factorial design 54 Randomized Phase II 54 adjuvant colon cancer 54 ANCHOR trial 54 Phase IIIb study 54 ENMD # 54 epirubicin cyclophosphamide 54 locoregional 54 Intracoronary 54 RenalGuard System TM 54 plus gemcitabine 54 IV NSCLC 54 NEO3 54 relapsing multiple sclerosis 54 CORD II 54 multicentre study 54 blinded randomized 54 viral kinetics 54 unstable angina UA 54 Combo Stent 54 platinum refractory 54 eculizumab therapy 54 TIMP 1 54 Stenting Trial 54 EmbraceAC 54 prospective observational studies 54 NSABP C 54 Feasibility Trial 54 NCT# 54 MACCE 54 Xelox 54 Pegylated Liposomal Doxorubicin 54 IIIb 54 ATACAND 54 % CI #.#-#.# [003] 54 ONTARGET R 54 RE COVER 54 liver resection 54 pharmacokinetic characteristics 54 Vasogen Celacade 54 induced macular edema 54 Phase IIa clinical 54 PRoFESS 54 cTnI 54 PRE SURGE 54 Zevalin consolidation 54 OvaRex ® MAb 54 Multi Ethnic Study 54 placebo PBO 54 Proellex TM 54 REVIVE TA 54 miRview mets 54 randomized 54 anti arrhythmic drug 54 metastatic renal cell carcinoma 54 huC# DM4 54 Endovascular Valve Edge 54 AIM HIGH 54 evaluating Vectibix 54 Zemplar Capsules 54 Stent Thrombosis 54 Screening Trial 54 Oral Fingolimod 54 sorafenib Nexavar 54 Betaferon ® 54 pancreatic adenocarcinoma 54 regorafenib 54 intraobserver 54 UPLYSO 54 TM Drug Eluting 54 virological response 54 percutaneous interventions 54 azacitidine 54 IMPROVE HF 54 Prostate Cancer Prevention 54 iodixanol 54 HYVET 54 OZURDEX 54 eplerenone 54 NTx 54 chromosome #p# [002] 54 lorvotuzumab mertansine 54 OPT CHF 54 ximelagatran 54 Pivotal Clinical Trial 54 heavily pretreated 54 REYATAZ r 54 HER2 positive metastatic breast 54 CR# vcMMAE 54 CLL SLL 54 TAXUS Element 54 TELCYTA 54 Zyclara 54 cortical stimulation 54 APEX AMI trial 54 virus HCV protease inhibitor 54 colesevelam HCl 54 metastatic castration resistant 54 Pivotal Phase 54 dose cohorts 54 Resolute DES 54 MoxDuo TM IR 54 fluoropyrimidine 54 CA4P 54 Phase 2b study 54 randomized crossover 54 Imprime PGG 54 relapsing remitting MS RRMS 54 mg/m2 dose 54 TAXUS Express2 paclitaxel eluting 54 safety tolerability pharmacokinetics 54 orally administered inhibitor 54 PHX# 54 intracoronary 54 SNP rs# [002] 54 Clinical Outcomes Utilizing Revascularization 54 tolvaptan 54 Phase 1b trial 54 Free Survival PFS 54 refractory colorectal cancer 54 Baseline characteristics 54 chlorambucil 54 Coronary Stent 54 GENASIS clinical 54 Refractory Angina 54 recurrent glioma 54 histologically confirmed 54 vitro cytotoxicity 54 transthoracic 54 PI3K/Akt pathway inhibitor 54 deferiprone 54 Pharmacokinetics PK 54 tirofiban 54 undergoing coronary artery 54 SVR# 54 inhibitor RG# 54 TAVR 54 OPCAB 54 periprocedural 54 ILUVIEN 54 safety tolerability pharmacokinetic 54 COPERNICUS 54 basal bolus regimen 54 dose escalation phase 54 carotid artery stent 54 clinical pharmacology studies 54 mapatumumab 54 Endeavor DES 54 CardioFit 54 relapsed MCL 54 hemodynamically significant 54 NICE SUGAR 54 virologic 54 Bayer HealthCare Onyx Pharmaceuticals 54 serum phosphorous 54 LV dysfunction 54 gadolinium enhanced 54 TRANSFORMS 54 Randomized Double blind 54 NOD SCID mice 54 INCB# [001] 54 insulin detemir 54 FOLPI 54 pegylated interferon alfa 2b 54 EQUIP OB 54 Virulizin ® 54 telaprevir dosed 54 PROMUS TM 54 unstable angina pectoris 54 resected pancreatic cancer 54 multicentric 54 CA9 SCAN 54 antiangiogenic therapy 54 subgroup analyzes 54 Phase 1b 54 Multicenter Randomized 54 STARFlex 54 FDG PET imaging 54 bosentan 54 papillary renal cell carcinoma 54 myocardial viability 54 multicenter trials 54 biochemical relapse 54 Pharmacokinetic parameters 53 Eluting Stent 53 PressureWire 53 rALLy trial 53 blind randomized 53 CTRC AACR San Antonio 53 naïve HCV 53 YONDELIS 53 lumbar spine BMD 53 Eluting Coronary Stent System 53 Taxus Liberte 53 dose regimens 53 IIa clinical 53 taxane resistant 53 functional mitral regurgitation 53 HORIZONS AMI 53 receptor tyrosine kinase inhibitor 53 Carotid 53 IL#B 53 HeartMate XVE 53 TEC #OL 53 prespecified secondary 53 cilengitide 53 Genous 53 LHRH receptor positive 53 varespladib 53 Optical Coherence Tomography 53 stenoses 53 urinary N telopeptide 53 oncolytic vaccine 53 stage IIIB 53 PD2i R 53 prostate cancer CaP 53 metastatic neuroendocrine tumors 53 ABSSSI 53 ICON7 53 Trandolapril 53 COR Analyzer 53 Platinol ® cisplatin 53 pegylated liposomal doxorubicin PLD 53 Swedish Mammography Cohort 53 neoadjuvant treatment 53 ThermoDox ® clinical 53 Traficet EN 53 paroxysmal AF 53 achieved statistical significance 53 T2 lesions 53 mg QD 53 Safinamide 53 XELOX 53 Major Adverse Cardiac 53 Polyp Prevention Trial 53 R# #mg BID 53 clinically evaluable 53 somatostatin analogue 53 Multicenter AIDS 53 unblinding 53 TAXUS Element Paclitaxel Eluting 53 carotid IMT 53 LUMINATE 53 telaprevir dosing 53 subcutaneous SC 53 myocardial necrosis 53 BAL# [002] 53 bepotastine besilate nasal spray 53 reinfarction 53 Liraglutide Effect 53 HSCT 53 AEGR 53 By JENNIFER LEARN 53 atherothrombotic disease 53 bevacizumab Avastin R 53 patients undergoing percutaneous 53 IMPACT DCM clinical 53 StemEx R 53 STARFlex R 53 COU AA 53 Thorough QT 53 radiographic outcomes 53 randomized placebo 53 PROactive Study 53 glycated hemoglobin levels 53 coronary lesions 53 Ambulatory Blood Pressure 53 Asthma Intervention 53 zalutumumab 53 transesophageal 53 PRECISE 53 Phase Ib IIa clinical 53 platinum chromium alloy 53 ejection fractions 53 Resten NG 53 MEK inhibitor RDEA# 53 sequential dose escalation 53 null responder HCV 53 mg BID 53 paclitaxel poliglumex 53 ALLHAT 53 NP2 Enkephalin 53 PROTEGE 53 GEM OS2 53 ug dose 53 cinacalcet 53 NuroPro PD 53 ABSORB 53 AIR CF1 53 subcutaneously administered 53 Aflibercept 53 EDEMA4 53 Screening Trial DMIST 53 Arimidex Tamoxifen Alone 53 NYHA Class II 53 Figure 2C 53 lumiliximab 53 tesmilifene 53 NADiA ProsVue 53 Tryton stent 53 IMA# 53 specified primary endpoint 53 percutaneous cryoablation 53 catheter occlusion 53 Monitoring ABPM 53 pertuzumab 53 HGS# 53 randomized discontinuation 53 pharmacodynamic effects 53 sunitinib Sutent 53 TIMI Study Group 53 relapsed myeloma 53 metastatic RCC 53 demonstrated clinically meaningful 53 Placebo controlled 53 PREVENT IV 53 USpella 53 Group B CALGB 53 LymphoStat B belimumab 53 MADIT 53 ORACLE MS 53 AtherOx 53 miRview ™ squamous